Apyx Medical Corporation Announces Proposed Public Offering of Common Stock

Medical Corporation Announces Proposed Public Offering of Common Stock

FL, November 17, 2025 -Apyx Medical Corporation (Nasdaq: APYX) (the "Company" or "Apyx Medical") the

leader in surgical aesthetics marketed and sold as Renuvion and the AYON Body Contouring System (AYON), today announced that

it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject

to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or

terms of the offering.

Capital Markets is acting as the sole book-running manager for the offering.

offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-268532) filed with the Securities and Exchange

Commission ("SEC") on November 22, 2022, and declared effective by the SEC on December 2, 2022.

preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available

on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the

offering, when available, may also be obtained by contacting Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York,

press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale

of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration

or qualification under the securities laws of any such state or other jurisdiction.

Feffer, Managing Director LifeSci Advisors

Apyx Medical Corporation:

Medical Corporation is a surgical aesthetics company with a passion for elevating people's lives through innovative products, including

its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring SystemTM in the

cosmetic surgery market and J-Plasma in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability

to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more

than 90 clinical documents. The AYON Body Contouring SystemTM is an FDA-cleared, groundbreaking, surgeon-designed body contouring

system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop

contouring, tissue contraction, and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring

treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements

with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical

Corporation website at www.ApyxMedical.com.

Statement on Forward-Looking Statements:

matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company

believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance

that its expectations will be achieved.

statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not

limited to, statements regarding the Company's anticipated public offering, including the completion of the public offering on

the anticipated terms, if at all, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial

items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency

or instrumentality including but not limited to the U.S. Food and Drug Administration (the "FDA"), supply chain disruptions,

component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those

matters on the Company's financial performance.

statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially

from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may

cause the Company's actual results to differ materially and that could impact the Company and the statements contained in this

release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company

is subject to, including the Company's ability to gain requisite approvals for its products from the FDA and other governmental

and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including

supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical

environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations;

and other risks that are described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and

the Company's other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company

claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of

1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information,

future events or otherwise.